BOOKMARK
  • Korean|
  • Chinese|
  • Japanese|
  • Vietnamese
본문내용 바로가기

Aju Business Daily

SEARCH
  • ECONOMY
  • ENTERTAINMENT
  • IT
  • South Korea
  • North Korea
  • WORLD
  • SPORTS
  • LIFESTYLE
  • AUTO MOTIVE
  • OPINION
  • PEOPLE
  • MILITARY
Home > Health > article

Daewoong seeks Philippine approval to test tapeworm treatment medicine

Lim Chang-won Reporter(cwlim34@ajunews.com) | Posted : July 8, 2020, 15:51 | Updated : July 8, 2020, 15:51
  • 트위터
  • 페이스북
  • 웨이보

[Courtesy of Daewoong ]


SEOUL -- Daewoong Pharmaceutical, a major bioengineering company in South Korea, has applied for approval by a Philippine health regulatory agency to test niclosamide (DWRX2003), a tapeworm treatment medicine selected as a candidate for COVID-19 antibody treatment.

Daewoong said it has sent an investigational new drug (IND) application to the Food and Drug Administration of the Philippines. If approval comes, the company will go ahead with the first-stage clinical trial of DWRX2003 in the Southeast Asian country. A similar application was made in India in May.

Daewoong claimed to have achieved progress in the initial animal testing of niclosamide. Institut Pasteur Korea, an infectious disease-focused research institute, works with a subsidiary of Daewoong to test the efficacy of niclosamide, which basically starves tapeworms to death by inhibiting the glucose uptake, oxidative phosphorylation and anaerobic metabolism.

To find COVID-19 treatment, Daewoong is also testing the effectiveness of mesenchymal stem cells (MSCs) and camostat mesilate, a potent serine protease inhibitor sold under the brand of Foistar. Foreign studies showed that camostat mesilate was found to be effective in blocking the spread and pathogenesis of COVID-19 in animal testing.

 

  • Lim Chang-won Reporter
  • email : cwlim34@ajunews.com
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.
  • twitter
  • facebook
  • weibo
  • link copy
  • LIST
  • TOP

Related news

  • .Medytox acquires 16.7% stake in Daewoongs U.S. partner for ending legal battle.
    Medytox acquires 16.7% stake in Daewoong's U.S. partner for …
  • .  Daewoong allowed to conduct Foistars clinical testing as COVID-19 treatment .
    Daewoong allowed to conduct Foistar's clinical testing as …
  • .Daewoong allowed to conduct third-stage combination therapy with diabetes drug candidate.
    Daewoong allowed to conduct third-stage combination therapy …
  • .Daewoong allowed to test efficacy of tapeworm treatment medicine in Philippines.
    Daewoong allowed to test efficacy of tapeworm treatment medi…
  • .Daewoong tests camostat mesilate for treatment of COVID-19.
    Daewoong tests camostat mesilate for treatment of COVID-19

Real Time Photo News

  • .BLACKPINK member Rosé to release solo album in March.

    BLACKPINK member Rosé to release solo album in March

  • .BTS agency posts record earnings in 2020 on brisk online activities and album sales .

    BTS agency posts record earnings in 2020 on brisk online activities and album sales

  • .[FOCUS] BTS agency leagues with Universal Music to launch new K-pop band in US music scene.

    [FOCUS] BTS agency leagues with Universal Music to launch new K-pop band in US music scene

  • .CJ ENM aims to become major visual content producer thru partnership with Epic Games .

    CJ ENM aims to become major visual content producer thru partnership with Epic Games

  • .​Solo singer Sunmi to come back with new album Tail.

    ​Solo singer Sunmi to come back with new album 'Tail'

Latest News

more+

  • Hyundai auto group forges hydrogen alliance with SK Group
  • Scuba diving in Cebu cited as most viewed content in LG Uplus VR platform
  • SKT uses VR platform to hold non-face-to-face entrance ceremony for university freshmen
  • Hyundai auto group holds groundbreaking ceremony for fuel cell plant in China
  • BLACKPINK member Rosé to release solo album in March
Aju Business Daily
  • ABOUT US
  • CONTACT US
  • PRIVACY STATEMENT
  • Copyright Policy

Address : Aju News Corporation LEEMA Building, 11th floor, 42, Jong-ro 1-gil, Jongno-gu, Seoul.    Mail : swatchsjp@ajunews.com

Copyright ⓒ 2016 By Ajunews Corporation, All Rights Reserved.

Mobile view